MedCity News February 20, 2025
Improving the identification and validation of disease-specific drug targets in a cell-type and patient-specific manner early on will not only reduce the failure rate and cost that is so inherent in current drug development processes but also allow the development of more effective precision medicines, improving patient outcomes.
The biggest challenge in drug development is that the process is not an even balance of hit or miss – it is overwhelmingly miss, with around 90% of drugs never making it beyond clinical trials. As a consequence, the cost of developing and bringing a single drug to market is estimated at $2.3 billion. This high attrition rate is a major challenge across the pharmaceutical industry, with strategies to address this inefficiency...
Today's Sponsors
Today's Sponsor